Ophthalmic solutions
An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.
1. An ophthalmically compatible solution, consisting of:
(a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
(b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
(c) sodium chloride, potassium chloride or any combination thereof;
(d) one or more buffers;
(e) glycerol; and
(f) water;
wherein the ophthalmically compatible solution is preservative-free.
2. The ophthalmically compatible solution of claim 1 , consisting of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; and
about 0.05 to about 0.5 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol.
3. The ophthalmically compatible solution of claim 1 , consisting of:
about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.1 to about 10% (w/w) of the one or more buffers.
4. The ophthalmically compatible solution of claim 1 , wherein the one or more buffers comprise boric acid or a salt thereof.
5. The ophthalmically compatible solution of claim 1 , consisting of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
about 0.05 to about 0.5 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol.
6. The ophthalmically compatible solution of claim 1 , in the form of eye drops.
7. A method for reducing, ameliorating, treating, or controlling a condition of dry eye, the method consisting of:
administering to an affected eye of a patient an ophthalmically compatible solution consisting of (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; (d) one or more buffers; and (e) glycerol; and (f) water;
wherein the ophthalmically compatible solution is preservative-free.
8. The method of claim 7 , wherein the ophthalmically compatible solution consists of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
about 0.08 to about 0.4 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
about 0.01 to about 0.08 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol.
9. The method of claim 7 , wherein the ophthalmically compatible solution is in the form of eye drops.
10. A method of rewetting a cornea, the method consisting of:
administering an ophthalmically compatible solution to a cornea, wherein the ophthalmically compatible solution consists of (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; (d) one or more buffers; (e) glycerol; and (f) water;
wherein the ophthalmically compatible solution is preservative-free.
11. The method of claim 10 , wherein the ophthalmically compatible solution consists of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
about 0.08 to about 0.4 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
about 0.01 to about 0.08 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol.
12. The method of claim 10 , wherein the ophthalmically compatible solution is in the form of eye drops.
13. A system useful as an artificial tear or for rewetting or lubricating a cornea, the system comprising a drop dispenser capable of holding between about 1 and about 30 ml of the ophthalmically compatible solution of claim 1 .
14. An ophthalmically compatible solution, consisting of:
(a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
(b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
(c) sodium chloride, potassium chloride or any combination thereof;
(d) one or more buffers;
(e) about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol; and
(f) water;
wherein the ophthalmically compatible solution is preservative-free.
15. The ophthalmically compatible solution of claim 14 , wherein the one or more buffers are selected from the group consisting of boric acid and a salt of boric acid.
16. The ophthalmically compatible solution of claim 14 , in the form of eye drops.
17. The ophthalmically compatible solution of claim 14 , consisting of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
about 0.08 to about 0.4 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
about 0.01 to about 0.08 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol.
18. The ophthalmically compatible solution of claim 14 , wherein the hyaluronic acid or a salt thereof is sodium hyaluronate.
19. The system according to claim 13 , wherein the ophthalmically compatible solution consists of:
about 0.01 to about 0.2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
about 0.05 to about 0.5 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of the sodium chloride, potassium chloride or any combination thereof; and
about 0.01 to about 5 wt. %, based on the total weight of the ophthalmically compatible solution, of glycerol.
20. The system according to claim 13 , wherein the one or more buffers are selected from the group consisting of boric acid and a salt of boric acid.
21. The system according to claim 13 , wherein the ophthalmically compatible solution is in the form of eye drops.